Suicide gene therapy with the yeast fusion gene cytosine deaminase/uracil phosphoribosyltransferase is not enough for pancreatic cancer

Pancreas

Volumn 35, Issue 3, 2007, Pages 224-231

  Fogar, Paola ^a   Navaglia, Filippo ^a   Basso, Daniela ^a   Greco, Eliana ^a   Zambon, Carlo Federico ^a   Fadi, Elisa ^a   Falda, Alessandra ^a   Stranges, Alessia ^a   Vannozzi, Francesca ^b   Danesi, Romano ^b   Pedrazzoli, Sergio ^a,c   Plebani, Mario ^a,c  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

5 fluorocytosine; 5 fluorouracil; Cytosine deaminase; Gene therapy; Pancreatic cancer; Phosphoribosyltransferase

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; PLASMID VECTOR; URACIL PHOSPHORIBOSYLTRANSFERASE;

ARTICLE; CHIMERA; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; GENE EXPRESSION; GENE FUSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SUICIDE GENE THERAPY;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; BIOTRANSFORMATION; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYTOSINE DEAMINASE; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FLUCYTOSINE; GENES, TRANSGENIC, SUICIDE; HUMANS; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PENTOSYLTRANSFERASES; PRODRUGS; RECOMBINANT FUSION PROTEINS; SACCHAROMYCES CEREVISIAE PROTEINS; THYMIDYLATE SYNTHASE; TRANSFECTION; URACIL NUCLEOTIDES;

EID: 34748848697     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/mpa.0b013e3180622519     Document Type: Article

References (35)

1. Stocken DD, Büchler MW, Dervenis C, et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer. 2005;92:1372-1381.
2. Ammori JB, Colletti LM, Zalupski MM, et al. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg. 2003;7:766-772.
3. Goldstein D, Carroll S, Apte M, et al. Modern management of pancreatic carcinoma. Intern Med J. 2004;34:475-481.
4. Freelove R, Walling AD. Pancreatic cancer: diagnosis and management. Am Fam Physician. 2006;73:485-492.
5. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330-338.
6. El-Khoueiry AB, Lenz H-J. Should continuous infusion 5-fluorouracil become the standard of care in the USA as it is in Europe? Cancer Invest. 2006;24:50-55.
7. Vermes A, Guchelaar H-J, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother. 2000;46:171-179.
8. Greco O, Dachs GU. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol. 2001;187:22-36.
9. Kuriyama S, Kikukawa M, Masui K, et al. Cytosine deaminase/5- fluorocytosine gene therapy can induce efficient anti-tumor effects and protective immunity in immunocompetent mice but not in athymic nude mice. Int J Cancer. 1999;81:592-597.
10. Kuriyama S, Mitoro A, Yamazaki M, et al. Comparison of gene therapy with the herpes simplex virus thymidine kinase gene and the bacterial cytosine deaminase gene for the treatment of hepatocellular carcinoma. Scand J Gastroenterol. 1999;34:1033-1041.
11. Shirakawa T, Gardner TA, Ko S-C, et al. Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model. J Urol. 1999;162:949-954.
12. Akbulut H, Tang Y, Maynard J, et al. Vector targeting makes 5-fluorouracil chemotherapy less toxic and more effective in animal models of epithelial neoplasms. Clin Cancer Res. 2004;10:7738-7746.
13. Hwang K-S, Cho W-K, Yoo J, et al. Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice. BMC Cancer. 2005;5:51.
14. Li S, Yu B, An P, et al. Combined liposome-mediated cytosine deaminase gene therapy with radiation in killing rectal cancer cells and xenografts in athymic mice. Clin Cancer Res. 2005;11:3574-3578.
15. Liu Y, Ye T, Maynard J, et al. Engineering conditionally replication-competent adenoviral vectors carrying the cytosine deaminase gene increases the infectivity and therapeutic effect for breast cancer gene therapy. Cancer Gene Ther. 2006;13:346-356.
16. Walther W, Stein U, Fichtner I, et al. Nonviral jet-injection gene transfer for efficient in vivo cytosine deaminase suicide gene therapy of colon carcinoma. Mol Ther. 2005;12:1176-1184.
17. Evoy D, Hirschowitz EA, Naama HA, et al. In vivo adenoviral-mediated gene transfer in the treatment of pancreatic cancer. J Surg Res. 1997;69:226-231.
18. Humphreys MJ, Greenhalf W, Neoptolemos JP, et al. The potential for gene therapy in pancreatic cancer. Int J Pancreatol. 1999;26:5-21.
19. Rigg AS, Lemoine NR. Genetic prodrug activation therapy for pancreatic cancer. Ann N Y Acad Sci. 1999;880:319-325.
20. Erbs P, Regulier E, Kintz J, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res. 2000;60:3813-3822.
21. Kanyama H, Tomita N, Yamano T, et al. Usefulness of repeated direct intratumoral gene transfer using hemagglutinating virus of Japan-liposome method for cytosine deaminase suicide gene therapy. Cancer Res. 2001;61:14-18.
22. Gilliam AD, Watson SA. Emerging biological therapies for pancreatic carcinoma. Eur J Surg Oncol. 2002;28:370-378.
23. Oonuma M, Sunamura M, Motoi F, et al. Gene therapy for intraperitoneally disseminated pancreatic cancers by Escherichia coli uracil phosphoribosyltransferase (UPRT) gene mediated by restricted replication-competent adenoviral vectors. Int J Cancer. 2002;102:51-59.
24. Katz MH, Bouvet M. Novel gene therapy approaches to pancreatic cancer. Int J Gastrointest Cancer. 2003;33:89-97.
25. Deharvengt S, Wack S, Aprahamian M, et al. Transcriptional tumor-selective promoter targeting of E. coli purine nucleoside phosphorylase for pancreatic cancer suicide gene therapy. J Gene Med. 2005;7:672-680.
26. Yoshida T, Ohnami S, Aoki K. Development of gene therapy to target pancreatic cancer. Cancer Sci. 2004;95:283-289.
27. Fogar P, Greco E, Basso D, et al. Killer genes in pancreatic cancer therapy. Cell Mol Biol. 2005;51:61-76.
28. Wang XP, Yazawa K, Yang J, et al. Specific gene expression and therapy for pancreatic cancer using the cytosine deaminase gene directed by the rat insulin promoter. J Gastrointest Surg. 2004;8:98-108.
29. Fogar P, Greco E, Basso D, et al. Suicide gene therapy with HSV-TK in pancreatic cancer has no effect in vivo in a mouse model. Eur J Surg Oncol. 2003;29:721-730.
30. Greco E, Fogar P, Basso D, et al. Retrovirus-mediated herpes simplex virus thymidine kinase gene transfer in pancreatic cancer cell lines: an incomplete antitumor effect. Pancreas. 2002;25:E21-E29.
31. Fischer U, Steffens S, Frank S, et al. Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. Oncogene. 2005;24:1231-1243.
32. Wu DH, Liu L, Chen LH. Antitumor effects and radiosensitization of cytosine deaminase and thymidine kinase fusion suicide gene on colorectal carcinoma cells. World J Gastroenterol. 2005;11:3051-3055.
33. Boucher PD, Im MM, Freytag SO, et al. A novel mechanism of synergistic cytotoxicity with 5-fluorocytosine and ganciclovir in double suicide gene therapy. Cancer Res. 2006;66:3230-3237.
34. Di Paolo A, Danesi R, Ciofi L, et al. Improved analysis of 5-fluorouracil and 5,6-dihydro-5-fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling. Ther Drug Monit. 2005;27:362-368.
35. Giovannetti E, Mey V, Nannizzi S, et al. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther. 2006;5:1387-1395.